AbbVie's Venetoclax Patent Refused in India: When a Genus Claim Outgrows Its Own Data
By Prashant Kotian, PhD Researcher (Chemistry), ICT Mumbai
Venetoclax is not an obscure molecule. Sold as Venclexta in the US and Venclyxto in most of the rest of the world, it is a Bcl-2 inhibitor that gave patients with chronic lymphocytic leukemia and acute myeloid leukemia something genuinely new: a pill that forces cancer cells back into the apoptosis pathway they had learned to switch off. It is a real blockbuster, jointly developed by AbbVie and Roche's Genentech. Its foundational Indian patent application just failed, and the reason is a straightforward chemistry problem, not a procedural technicality.
AbbVie's application, no. 8004/DELNP/2011, titled "Apoptosis-Inducing Agents for the Treatment of Cancer and Immune and Autoimmune Diseases," did not claim venetoclax as a single molecule. It claimed a Markush genus: a general formula (the application labels it Formula II) built around a sulfonamide core, with enough substituent variation at the R-group positions to cover thousands of distinct compounds. Venetoclax is simply one specific member sitting inside that broad structural family. This is a completely ordinary way to draft a pharmaceutical patent. Genus claims exist precisely because a company that has found one active compound in a family usually wants to fence off the whole family, not just the one molecule it happened to test first.
The problem, according to the Deputy Controller of Patents and Designs, who rejected the application on 31 December 2025 after seven pre-grant oppositions filed between 2018 and 2025, is what backed that fence. The specification's actual Bcl-2 inhibition data covered only a handful of compounds out of the thousands the claims swept in. Two prior-art documents, US 2007/0015787A1 and WO 2005/049593A2, already disclosed structurally comparable sulfonamide apoptosis-promoting compounds. Against that backdrop, the Controller held that a person skilled in the art could arrive at the claimed genus without an inventive step, that the application failed to show enhanced therapeutic efficacy over what was already known as required under Section 3(d), and that the disclosure itself was insufficient to support a claim of this breadth.
Most of the recent genus claim fights in Indian pharma litigation run the other direction: an early, broad Markush patent gets used defensively to block a company's own later, narrower species patent on the same family, on the theory that the genus already covered the specific compound even without describing it by name. This case is the mirror image. Here the genus claim itself was the thing under attack, and it lost because the applicant's own specification could not carry the weight of what it was asking the claims to cover. Running a real binding assay on a representative handful of compounds and then claiming inventive step and enhanced efficacy across an entire structural family of thousands is a common drafting habit in this industry. The Controller's order is a reminder that the burden of proof scales with the size of the genus claimed, not with the size of the dataset a company is willing to generate.
This is not the end of the story for AbbVie in India. The company retains the right to appeal this refusal, and as of this writing there is no public record that it has done so. A separate AbbVie application tied to venetoclax's composition remains under its own, independent opposition and is not resolved by this order. What is resolved, for now, is the foundational compound family claim, and Indian oncology generic manufacturers with existing Bcl-2 inhibitor API capability are watching the same file we are.
Why it matters: pre-grant opposition in India is where a large share of the real evidentiary fights over Markush genus claims actually happen, long before any of it reaches a courtroom. A generic manufacturer or CDMO evaluating freedom to operate on a genus patented target should treat how much of the claimed genus is actually supported by data as a first pass screening question, not an afterthought reserved for litigation.
What we do
See if this applies to one of your matters
We run genus/species (Markush) claim coverage analysis, Section 3(d) compliance screening, and prior-art structural triage on real chemical structures — not keyword search. If a case like this one is live for you, we'll run a free sample on a compound of your choosing.